Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.

导出 LinkOut

翻译打印收藏纠错

第一作者： Martha F,Wright

第一单位： Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

作者： Martha F,Wright ^[1] ; Olga,Pozdnyakova ^[2] ; Robert P,Hasserjian ^[3] ; Nidhi,Aggarwal ^[4] ; Aaron C,Shaver ^[1] ; Olga K,Weinberg ^[5] ; Rebecca,Irlmeier ^[6] ; Tatsuki,Koyama ^[6] ; Adam C,Seegmiller ^[1] ; Stephen A,Strickland ^[7] ; Emily F,Mason ^[1]

作者单位： Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. ^[1] Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ^[2] Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. ^[3] Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. ^[4] Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. ^[5] Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. ^[6] Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. ^[7]

主题词人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);预后(Prognosis);突变(Mutation);核蛋白质类(Nuclear Proteins)

DOI 10.1002/ajh.26730

PMID 36106410

发布时间 2025-02-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交